MicroRNA-103a-3p controls proliferation and osteogenic differentiation of human adipose tissue-derived stromal cells

The elucidation of the molecular mechanisms underlying the differentiation and proliferation of human adipose tissue-derived stromal cells (hADSCs) represents a critical step in the development of hADSCs-based cellular therapies. To examine the role of the microRNA-103a-3p (miR-103a-3p) in hADSCs functions, miR-103a-3p mimics were transfected into hADSCs in order to overexpress miR-103a-3p. Osteogenic differentiation was induced for 14 days in an osetogenic differentiation medium and assessed by using an Alizarin Red S stain. The regulation of the expression of CDK6 (cyclin-dependent kinase 6), a predicted target of miR-103a-3p, was determined by western blot, real-time PCR and luciferase reporter assays. Overexpression of miR-103a-3p inhibited the proliferation and osteogenic differentiation of hADSCs. In addition, it downregulated protein and mRNA levels of predicted target of miR-103a-3p (CDK6 and DICER1). In contrast, inhibition of miR-103a-3p with 2′O methyl antisense RNA increased the proliferation and osteogenic differentiation of hADSCs. The luciferase reporter activity of the construct containing the miR-103a-3p target site within the CDK6 and DICER1 3′-untranslated regions was lower in miR-103a-3p-transfected hADSCs than in control miRNA-transfected hADSCs. RNA interference-mediated downregulation of CDK6 and DICER1 in hADSCs inhibited their proliferation and osteogenic differentiation. The results of the current study indicate that miR-103a-3p regulates the osteogenic differentiation of hADSCs and proliferation of hADSCs by direct targeting of CDK6 and DICER1 partly. These findings further elucidate the molecular mechanisms governing the differentiation and proliferation of hADSCs. A short, non-coding RNA molecule blocks the ability of fat-derived stem cells to turn into bone tissue. Jin Sup Jung and colleagues from Pusan National University School of Medicine in South Korea isolated stem cells from human fat tissue and cultured the cells in a bone-forming medium. They boosted the expression of microRNA-103a-3p — a known regulator of bone development in mice — and observed slower growth and less differentiation toward bone cells. Blocking the microRNA's activity had the opposite effect. The researchers showed that microRNA-103a-3p prevents bone formation, at least in part, by inhibiting two genes: CDK6 and DICER1. The authors suggest that drugs designed to disrupt microRNA-103a-3p activity could help treat bone disease. Therapies involving fat-derived stem cells could also benefit from including a microRNA-103a-3p blocking agent.